In line with this, PGRMC1 silencing favored an enhanced NFAT1 accumulation in cells treated with P4 (Figure 9), thus favoring cell proliferation similar to that in prostate cancer cells [71,72]. Here, NFATC2 is linked to prostate carcinoma.